INmune Bio Sees Significant Short Interest Decline

Hedge funds and institutional investors adjust positions in the clinical-stage immunology company.

Apr. 1, 2026 at 8:22pm

Got story updates? Submit your updates here. ›

INmune Bio, Inc. (NASDAQ:INMB) saw a 14.5% decrease in short interest during March, with short positions dropping from 3.8 million shares to 3.3 million. The company's stock has traded in a range of $1.09 to $11.64 over the past year, with a current market capitalization of $32.69 million.

Why it matters

Changes in short interest can signal shifting market sentiment around a company, as investors bet on or against its future performance. INmune Bio's decline in short positions may indicate increased confidence in the clinical-stage immunology firm and its lead drug candidate XPro1595, which is designed to reduce chronic inflammation.

The details

INmune Bio's short interest decreased by 14.5% in March, from 3,806,985 shares to 3,256,235 shares. This represents approximately 15.5% of the company's outstanding stock. The average daily trading volume is 560,935 shares, putting the current short interest ratio at 5.8 days.

  • As of March 13, 2026, INmune Bio had 3,256,235 shares short.
  • On February 26, 2026, INmune Bio had 3,806,985 shares short.

The players

INmune Bio, Inc.

A clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat serious diseases.

XPro1595

INmune Bio's lead therapeutic candidate, a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation.

Got photos? Submit your photos here. ›

The takeaway

The decline in short interest for INmune Bio may signal increased investor confidence in the company's clinical pipeline and future prospects, particularly around its lead drug candidate XPro1595 and its potential to address chronic inflammation.